Beckman Coulter BioMek 2000 Workstation and Accessories

描述（由申请人提供）：用于基于流式细胞仪的自动化 免疫功能测定，要求提供资金购买贝克曼库尔特 BioMek 2000系统，位于Gladstone/UCSF核心免疫学 旧金山弗朗西斯科总医院实验室。核心实验室。的流程 已经开发并优化了基于细胞计数的测定系统，以检测 对HIV-1和巨细胞病毒（CMV）的特异性CD 4+和CD 8 + T细胞应答 在HIV-1感染者的队列中。与MHC I类四聚体测定不同， 这个吗？细胞因子流式细胞术（CFC）测定可用于检测T细胞 针对未定义抗原表位的应答 未鉴定的MHC背景相关的检测方法正在开发中， 评估特异性人CD 4+和CD 8 + T细胞对其他 艾滋病相关的机会性感染，包括由Mvcobacterium引起的机会性感染 肺结核、鸟分枝杆菌复合体、卡氏肺孢子虫和人 乳头瘤病毒UCSF的许多研究人员已经将CFC纳入他们的 研究方案;因此，在核心区进行的氟氯化碳测定的数量 实验室稳步快速增长。为了满足 这项服务，以提高安全性和可靠性，并进行实验 手动执行是不切实际或不可能，因此有必要 自动化CFC。结合已经到位的仪器， 仪器系统将允许CFC的自动化和进一步发展 分析，大大加强和提高核心的能力， 免疫学实验室，以支持许多格莱斯顿/加州大学旧金山分校的研究人员参与 艾滋病研究。此外，这些自动化检测将提供给 从事其他研究领域的科学家和来自其他领域的科学家 国家的部分地区（例如，通过艾滋病临床试验组）。的 选定的主要用户的科学兴趣和专门知识包括广泛的 生物学的光谱和免疫功能分析的统一重点; 因此，该仪器系统将支持范围广泛的项目 涉及在以下情况下评估T细胞应答：1）HIV-1 疫苗，2）抗逆转录病毒治疗失败，3）结构化治疗 中断，4）交叉分支识别，5）CTL动力学，6）宫颈HPV 发育不良，7）卡氏肺孢子虫感染，8）实体器官移植， 9)用DHEA的“替代疗法”，和10）CSF细胞增多。总之，这 拟议的仪器系统是成功的几个NIH资助的关键 调查和研究人员，将提供一个关键的资源， 格拉德斯通/加州大学旧金山分校的研究社区，并将激发创新的研究，在 未来

DESCRIPTION (provided by applicant): For the automation of flow cytometry-based assays of immune function, funding is requested to purchase a Beckman Coulter BioMek 2000 system, to be located in the Gladstone/UCSF Core Immunology Laboratory at San Francisco General Hospital. In the Core Laboratory. a flow cytometry-based assay system has been developed and optimized to detect specific CD4+ and CD8+ T cell responses to HIV-1 and to cytomegalovirus (CMV) in cohorts of HIV-1-infected patients. Unlike the MHC Class I tetramer assay, this ?cytokine flow cytometry (CFC) assay can be used to detect T cell responses against undefined antigenic epitopes in the context of uncharacterized MHC backgrounds. Related assays are being developed for the assessment of specific human CD4+ and CD8+ T cell responses to other AIDS-related opportunistic infections, including those caused by Mvcobacterium tuberculosis, the Mvcobacterium avium complex, Pneumocvstis carinii, and human papilloma virus. Many investigators at UCSF have incorporated CFC into their research protocols; consequently the number of CFC assays performed in the Core Laboratory is steadily and rapidly increasing. To keep up with the demand for this service, to improve safety and reliability, and to perform experiments that would be impractical or impossible to perform manually, it is necessary to automate CFC. Combined with the instrumentation already in place, the proposed instrument system will allow for the automation and further development of CFC assays, significantly strengthening and enhancing the ability of the Core Immunology Laboratory to support the many Gladstone/UCSF investigators engaged in HIV research. In addition, these automated assays will be made available to scientists engaged in other areas of research and to scientists from other parts of the country (e.g., through the AIDS Clinical Trials Group). The scientific interests and expertise of the selected major users include a broad spectrum of biology and a unifying focus on the analysis of immune function; consequently, the instrument system will support a broad range of projects involving the evaluation of T cell responses in the context of: 1) HIV-1 vaccines, 2) antiretroviral therapy failure, 3) structured treatment interruption, 4) cross clade recognition, 5) CTL dynamics, 6) HPV in cervical dysplasia, 7) Pneumocystis carinii infection, 8) solid organ transplantation, 9) "alternative therapy" with DHEA, and 10) CSF pleocytosis. In summary, this proposed instrument system is pivotal to the success of several NIH-funded investigations and researchers, will provide a critical resource to the Gladstone/UCSF research community, and will spark innovative research in the future.